{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:28:06Z","timestamp":1792081686922,"version":"4.4.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background: Simple, reproducible assays are needed for the quantification of sphingolipids, ceramide (Cer), and sphingoid bases. We developed an HPLC method for simultaneous quantification of total plasma concentrations of Cer, glucosylceramide (GlcCer), and ceramide trihexoside (CTH).<\/jats:p><jats:p>Methods: After addition of sphinganine as internal calibrator, we extracted lipids from 50 \u03bcL plasma. We deacylated Cer and glycosphingolipids by use of microwave-assisted hydrolysis in methanolic NaOH, followed by derivatization of the liberated amino-group with o-phthaldialdehyde. We separated the derivatized sphingoid bases and lysoglycosphingolipids by HPLC on a C18 reversed-phase column with a methanol\/water mobile phase (88:12, vol\/vol) and quantified them by use of a fluorescence detector at \u03bbex 340 nm and \u03bbem 435 nm.<\/jats:p><jats:p>Results: Optimal conditions in the Solids\/Moisture System SAM-155 microwave oven (CEM Corp.) for the complete deacylation of Cer and neutral glycosphingolipids without decomposition were 60 min at 85% power, fan setting 7. Intra- and interassay CVs were &amp;lt;4% and &amp;lt;14%, respectively, and recovery rates were 87%\u2013113%. The limit of quantification was 2 pmol (0.1 pmol on column), and the method was linear over the interval of 2\u2013200 \u03bcL plasma. In samples from 40 healthy individuals, mean (SD) concentrations were 9.0 (2.3) \u03bcmol\/L for Cer, 6.3 (1.9) \u03bcmol\/L for GlcCer, and 1.7 (0.5) \u03bcmol\/L for CTH. Plasma concentrations of GlcCer were higher in Gaucher disease patient samples and of CTH in Fabry disease patient samples.<\/jats:p><jats:p>Conclusions: HPLC enables quantification of total Cer, GlcCer, and CTH in plasma and is useful for the follow-up of patients on therapy for Gaucher or Fabry disease.<\/jats:p>","DOI":"10.1373\/clinchem.2006.079012","type":"journal-article","created":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T04:04:55Z","timestamp":1172808295000},"page":"742-747","source":"Crossref","is-referenced-by-count":90,"title":["HPLC for Simultaneous Quantification of Total Ceramide, Glucosylceramide, and Ceramide Trihexoside Concentrations in Plasma"],"prefix":"10.1093","volume":"53","author":[{"given":"Johanna EM","family":"Groener","sequence":"first","affiliation":[{"name":"Departments of Medical Biochemistry and Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben JHM","family":"Poorthuis","sequence":"first","affiliation":[{"name":"Departments of Medical Biochemistry and Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijmen","family":"Kuiper","sequence":"first","affiliation":[{"name":"Departments of Medical Biochemistry and Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette TJ","family":"Helmond","sequence":"first","affiliation":[{"name":"Departments of Medical Biochemistry and Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla EM","family":"Hollak","sequence":"first","affiliation":[{"name":"University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes MFG","family":"Aerts","sequence":"first","affiliation":[{"name":"Departments of Medical Biochemistry and Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,4,1]]},"reference":[{"key":"2020022802413980600_R1","unstructured":"Beutler E, Grabowski GA. Gaucher disease. Scriver CR Beaudet AL Sly WS Valle D eds. The Metabolic and Molecular Bases of Inherited Disease 8th ed 2001:3635-3668 McGraw-Hill New York. ."},{"key":"2020022802413980600_R2","doi-asserted-by":"crossref","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med1991;324:1464-1470.","DOI":"10.1056\/NEJM199105233242104"},{"key":"2020022802413980600_R3","unstructured":"Desnick RJ, Ioannou YA, Eng CM. \u03b1-Galactosidase A deficiency: Fabry disease. Scriver CR Beaudet AL Sly WS Valle D eds. The Metabolic and Molecular Bases of Inherited Disease 8th ed 2001:3733-3774 McGraw-Hill New York. ."},{"key":"2020022802413980600_R4","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Kopp JB, Austin HA, 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA2001;285:2743-2749.","DOI":"10.1001\/jama.285.21.2743"},{"key":"2020022802413980600_R5","doi-asserted-by":"crossref","unstructured":"Platt FM, Neises GR, Dwek RA, Butters TD. N-Butyl-deoxynojirimycin is a novel inhibitor of glycosphingolipid biosynthesis. J Biol Chem1994;269:8362-8365.","DOI":"10.1016\/S0021-9258(17)37202-2"},{"key":"2020022802413980600_R6","doi-asserted-by":"crossref","unstructured":"Cox T, Lachmann R, Hollak CE, Aerts J, van Weely S, Hrebicek M, et al. Novel oral treatment of Gaucher\u2019s disease with N-butyl-deoxynojirimycin (OGT918) to decrease substrate biosynthesis. Lancet2000;355:1481-1485.","DOI":"10.1016\/S0140-6736(00)02161-9"},{"key":"2020022802413980600_R7","doi-asserted-by":"crossref","unstructured":"Aerts JMEG, Hollak CEM, Boot RG, Groener JEM, Maas M. Substrate reduction therapy of glycosphingolipids storage disorders. J Inherit Metab Dis2006;29:448-455.","DOI":"10.1007\/s10545-006-0272-5"},{"key":"2020022802413980600_R8","doi-asserted-by":"crossref","unstructured":"Hannun YA, Obeid LM. The ceramide-centric universe of lipid mediated cell regulation: stress encounters of the lipid kind. J Biol Chem2002;277:25847-25850.","DOI":"10.1074\/jbc.R200008200"},{"key":"2020022802413980600_R9","doi-asserted-by":"crossref","unstructured":"Hakomori S. Structure, organization, and function of glycosphingolipids in membrane. Curr Opin Hematol2003;10:16-24.","DOI":"10.1097\/00062752-200301000-00004"},{"key":"2020022802413980600_R10","doi-asserted-by":"crossref","unstructured":"Cremesti AE, Fisch AS. Current methods for the identification and quantitation of ceramides: an overview. Lipids2002;35:937-945.","DOI":"10.1007\/s11745-000-0603-1"},{"key":"2020022802413980600_R11","doi-asserted-by":"crossref","unstructured":"Svennerholm S, Svennerholm L. The separation of neutral blood serum glycolipids by thin-layer chromatography. Biochim Biophys Acta1963;70:432-441.","DOI":"10.1016\/0006-3002(63)90773-X"},{"key":"2020022802413980600_R12","doi-asserted-by":"crossref","unstructured":"Berna L, Asfaw B, Conzelmann E, Cerny C, Ledvinova J. Determination of urinary sulfatides and other lipids by combination of reversed-phase and thin-layer chromatographies. Anal Biochem1999;269:304-311.","DOI":"10.1006\/abio.1999.4002"},{"key":"2020022802413980600_R13","doi-asserted-by":"crossref","unstructured":"Zeidner KM, Desnick RJ, Ioannou YA. Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit. Anal Biochem1999;267:104-113.","DOI":"10.1006\/abio.1998.2966"},{"key":"2020022802413980600_R14","doi-asserted-by":"crossref","unstructured":"Ullman MD, Pyeritz, Moser HW, Wenger DA, Kolodny EH. Application of \u201chigh-performance\u201d liquid chromatography to the study of sphingolipidosis. Clin Chem1980;26:1499-1503.","DOI":"10.1093\/clinchem\/26.10.1499"},{"key":"2020022802413980600_R15","doi-asserted-by":"crossref","unstructured":"Pons A, Popa J, Portoukalian J, Bodennec J, Ardail D, Kol O, et al. Single-step gas chromatography-mass spectrometry analysis of glycolipid constituents as heptafluorobutyrate derivatives with a special reference to the lipid portion. Anal Biochem2000;284:201-216.","DOI":"10.1006\/abio.2000.4686"},{"key":"2020022802413980600_R16","doi-asserted-by":"crossref","unstructured":"Fujiwaki T, Yamaguchi S, Tasaka M, Sakura N, Taketomi T. Application of delayed extraction-matrix-assisted laser desorption ionization time-of-flight mass spectrometry for analysis of sphingolipids in pericardial fluid, peritoneal fluid and serum from Gaucher disease patients. J Chromatogr B Analyt Technol Biomed Life Sci2002;776:115-123.","DOI":"10.1016\/S1570-0232(02)00177-0"},{"key":"2020022802413980600_R17","doi-asserted-by":"crossref","unstructured":"Nelson BC, Roddy T, Araghi S, Wilkens D, Thomas JJ, Zhang K, et al. Globotriaosylceramide isoform profiles in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci2004;805:127-134.","DOI":"10.1016\/j.jchromb.2004.02.032"},{"key":"2020022802413980600_R18","doi-asserted-by":"crossref","unstructured":"Mills K, Eaton S, Ledger V, Young E, Winchester B. The synthesis of internal standards for the quantitative determination of sphingolipids by tandem mass spectrometry. Rapid Commun Mass Spectrom2005;19:1739-1748.","DOI":"10.1002\/rcm.1977"},{"key":"2020022802413980600_R19","doi-asserted-by":"crossref","unstructured":"Levery SB. Glycosphingolipid structural analysis and glycosphingolipidomics. Methods Enzymol2005;405:300-369.","DOI":"10.1016\/S0076-6879(05)05012-3"},{"key":"2020022802413980600_R20","doi-asserted-by":"crossref","unstructured":"Merrill AH, Jr, Sullards MC, Allegood JC, Kelly S, Wang E. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods2005;36:207-224.","DOI":"10.1016\/j.ymeth.2005.01.009"},{"key":"2020022802413980600_R21","doi-asserted-by":"crossref","unstructured":"Suzuki Y, Suzuki M, Ito E, Goto-Inoue N, Miseki K, Iida J, et al. A convenient structural analysis of glycosphingolipids using MALDI-QIT-TOF mass spectrometry with increased laser power and cooling gas flow. J Biochem (Tokyo)2006;139:771-777.","DOI":"10.1093\/jb\/mvj090"},{"key":"2020022802413980600_R22","doi-asserted-by":"crossref","unstructured":"Taketomi T, Hara A, Uemura K, Kurahashi H, Sugiyama E. A microwave-mediated saponification of galactosylceramide and galactosylceramide I3-sulfate and identification of their lysocompounds by delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Biochem Biophys Res Commun1996;224:462-467.","DOI":"10.1006\/bbrc.1996.1049"},{"key":"2020022802413980600_R23","doi-asserted-by":"crossref","unstructured":"Itonori S, Takahashi M, Kitamura T, Aoki K, Dulaney JT, Sugita M. Microwave-mediated analysis for sugar, fatty acid, and sphingoid compositions of glycosphingolipids. J Lipid Res2004;45:574-581.","DOI":"10.1194\/jlr.D300030-JLR200"},{"key":"2020022802413980600_R24","doi-asserted-by":"crossref","unstructured":"Merrill AH, Jr, Wang E, Mullins RE, Jamison WCL, Nimkar S, Liotta DC. Quantitation of free sphingosine in liver by high-performance liquid chromatography. Anal Biochem1988;171:373-381.","DOI":"10.1016\/0003-2697(88)90500-3"},{"key":"2020022802413980600_R25","doi-asserted-by":"crossref","unstructured":"Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem1957;226:497-509.","DOI":"10.1016\/S0021-9258(18)64849-5"},{"key":"2020022802413980600_R26","doi-asserted-by":"crossref","unstructured":"Nilsson O, Hakansson G, Dreborg S, Groth CG, Svennerholm L. Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III. Clin Genet1982;22:274-279.","DOI":"10.1111\/j.1399-0004.1982.tb01445.x"},{"key":"2020022802413980600_R27","doi-asserted-by":"crossref","unstructured":"Erikson A, A\u030astro\u0308m M, Ma\u030ansson JE. Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease. Neuropediatrics1995;26:203-207.","DOI":"10.1055\/s-2007-979754"},{"key":"2020022802413980600_R28","doi-asserted-by":"crossref","unstructured":"Erikson A, Forsberg H, Nilsson M, A\u030astro\u0308m M, Ma\u030ansson JE. Ten years\u2019 experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease. Acta Paediatrica2006;95:312-317.","DOI":"10.1080\/08035250500423804"},{"key":"2020022802413980600_R29","doi-asserted-by":"crossref","unstructured":"Whitfield PD, Nelson P, Sharp PC, Bindloss CA, Dean C, Ravenscroft EM, et al. Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: Implication for the prediction of disease severity. Mol Genet Metab2002;75:46-55.","DOI":"10.1006\/mgme.2001.3269"},{"key":"2020022802413980600_R30","doi-asserted-by":"crossref","unstructured":"Vance DE, Krivit W, Sweeley CC. Concentration of glycosylceramides in plasma and red cells in Fabry\u2019s disease, a glycolipid lipidosis. J Lipid Res1969;10:188-192.","DOI":"10.1016\/S0022-2275(20)42667-7"},{"key":"2020022802413980600_R31","doi-asserted-by":"crossref","unstructured":"Boscaro F, Pieraccini G, la Marca G, Bartolucci G, Luceri C, Luceri F, et al. Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease. Rapid Commun Mass Spectrom2002;16:1507-1514.","DOI":"10.1002\/rcm.728"},{"key":"2020022802413980600_R32","doi-asserted-by":"crossref","unstructured":"Samuelson K. Identification and quantitative determination of ceramide in human plasma. Scan J Clin Lab Invest1971;27:371-380.","DOI":"10.3109\/00365517109080233"},{"key":"2020022802413980600_R33","doi-asserted-by":"crossref","unstructured":"Sugita M, Iwamori M, Evans J, McCluer RH, Dulaney JT, Moser HW. High performance liquid chromatography of ceramides: application to analysis in human tissues and demonstration of ceramide excess in Farber\u2019s disease. J Lipid Res1974;15:223-226.","DOI":"10.1016\/S0022-2275(20)36799-7"},{"key":"2020022802413980600_R34","doi-asserted-by":"crossref","unstructured":"Drobnik W, Liebisch G, Audebert F-X, Fro\u0308hlich D, Glu\u0308ck T, Vogel P, et al. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res2003;44:754-761.","DOI":"10.1194\/jlr.M200401-JLR200"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/53\/4\/742\/32689495\/clinchem0742.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/53\/4\/742\/32689495\/clinchem0742.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T09:46:17Z","timestamp":1628502377000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/53\/4\/742\/5627679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,1]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2007,4,1]]},"published-print":{"date-parts":[[2007,4,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2006.079012","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,4,1]]},"published":{"date-parts":[[2007,4,1]]}}}